Drug Approval | February 20, 2026
Johnson & Johnson bags FDA nod for monthly RYBREVANT FASPRO dosing in advanced lung cancer
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
The data highlights its RSV vaccine cuts hospitalizations in older adults
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
This transaction fundamentally strengthens Scinai's CDMO platform
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks
Subscribe To Our Newsletter & Stay Updated
